Our most recent druggability paper has attracted quite a lot of attention, apparently!
Find below the e-mail announcing Q3 access results. As you can see, we are in very good company indeed
January update.
The paper is still going strong: it remains in the top 20 most accessed (#15) 6 months after it was published